Home » Newsletters » BioWorld Science

BioWorld Science

July 26, 1996

View Archived Issues

RPR describes tachykinin NK1 antagonists

BMDB shows antinociceptive activity in mouse model

SEPA-ibuprofen formulation fares well in phase II trial

Chugai describes 24-oxo-22-oxavitamin D3 derivatives

Ulinastatin claimed by Mochida as skin disorder treatment

Human Genome Sciences claims VIGF polypeptide technology

Pimilprost shows wound healing properties in preclinical studies

SBI Skin Biology issued U.S. patent for Folligen and similar technology

Carbapenem derivatives with antibacterial activity claimed by Yamanouchi

Xoma claims rBPI21 + antibiotic combination for Gram-negative infections

Chlorhexidine gluconate effective in reducing incidence of nosocomial respiratory tract infections

Sequus and Zeneca restructure Amphotec marketing agreement

SmithKline Beecham acquires worldwide rights to Cantab's TA-GW vaccine

Gilead Science's sulfone HIV protease inhibitors

Allophenylnorstatine HIV protease inhibitors described

Sequus licenses liposome-CD4 technology

Columbia Laboratories' SPC3 undergoes phase I/II trials

Virulizin enters phase I/II for drug-resistant HIV-related Kaposi's sarcoma

TAR-PAK-140: University of Alberta's anti-HIV vector

Mulsal N shows significant CD4 cell count increases in trial

ZY-1 demonstrates therapeutic promise in HIV patients

CHAM3 induces clinical and biological improvement in HIV patients

Rz9456: Potential hematopoietic stem cell therapy for AIDS

Cyanovirin-N selected for high priority development by the National Cancer Institute

Immunogenic oligomeric HIV-1 gp160 vaccine described

rBCG-V3JI: Ajinomoto's vector-based vaccine

Vistide available in U.S. as CMV treatment in AIDS patients

COX-2 inhibitors described to treat inflammation

Monoclonal antibody fragments as immunosuppressants

Matrix metalloproteinase inhibitors described by British Biotech

Erythropoietin claimed as chronic inflammation treatment

World's first clinical trial on gene therapy for arthritis underway

HSV proteins as immune resonse regulators

Immunoregulatory peptides with special binding properties

Rapamycin esters from American Home Products

Biogal describes cyclosporin emulsions

Aphton announces commencement of phase III trials for Gastrimmune

Humanized CD38 antibodies for cancer/autoimmune disease treatment

Larifane shown effective in cervical dysplasia/cancer patients

IL-2/interferon alpha/5-FU combination effective against metastatic renal cancer

Protein farnesyltransferase inhibitors described by Warner-Lambert

Tyrosine kinase inhibitors in Pharmacia & Upjohn's pipeline

Octapeptide neuromedin B antagonists described

New formulation of CGP-41251

Human Genome Sciences' VIGF antagonists in pipeline

Anticancer oligonucleotides from Taiho

TPO711: Thrombopoietin useful as bone marrow cell proliferation therapy

Ethyol available on Canadian market

Ciclosporin demonstrates efficacy and safety as an antimetabolite

InSite Vision and Bausch & Lomb announce alliance regarding glaucoma drug

Fujisawa claims tacrolimus as allergic conjunctivitus treatment

Cefazolin/fluoroquinolone combinations show favorable antibacterial activity

Isolation of SOX-9 polypeptide encoding gene announced

Patent collaboration on bone morphogenetic/osteogenetic proteins

Boehringer Mannheim reveals acatelin, a novel ACAT inhibitor

SR-12813: SmithKline Beecham and Symphar's hypocholesterolemic drug

Celtrix's SomatoKine proven safe in phase I

Ibex licenses technology from Centre for Applied Microbiology and Research

Nicotrol launched on U.S. market as OTC

Contrast agents and antidotes described by Schering AG

Quidel's QuickVue Chlamydia Test approved in Germany

ICD grants exclusive rights of DR-70 to Y.H. BioTek

Oncor obtains license to p43 blood test for early-stage breast cancer

Cyogen's ProstaScint on its way to FDA approval

Positive safety profile reported on histamine H3 antagonist research

Pierre Fabre reports 5-HT1A agonists

Duloxetine claimed for new indication

Raloxifene indicated for excess NPY associated disorders

Ontogen and Kanebo enter drug development collaboration

Biogen and Ontogeny sign CNS drug development collaboration

Millennium and Wyeth-Ayerst collaborate on CNS drugs and gene therapies

Isis and ProtoGene renew drug discovery collaboration

Techniclone International issued European patent for its Modified Antibodies Technology

Ribozyme/Alza research collaboration

Guilford obtains rights to chemotherapy drug delivery system

Somatix acquires exclusive license to gene transfer technology

StressGen acquires rights to gene therapy technology

Synsorb Biotech licenses technology for enteropathogenic E. coli infection treatment

Enzon's SCA protein technology patent extended

ICN's investment in Eastern Europe

Sanofi to acquire Bock Pharmacal

Zynaxis to sell division to Seloc

Hoechst reorganizes German pharmaceutical activities

Chinoin describes new selegiline formulation

Yeda claims protein as potential autoimmune disease treatment

MBP peptide analogues described as multiple sclerosis treatment

Vanderbilt University describes ligands for 5-HT3 receptors

5-HT3/NK1 antagonist combination effective in emesis treatment and prevention

CP-122638: Pfizer's potential treatment for non-migraine emesis

ERT therapy enhances clinical response to tacrine in Alzheimer's patients

Immunex issued U.S. patent for Lerk-7

Research supports role of testosterone in pathogenesis of stroke

Bifemelane claimed for cerebrovascular disorders treatment

Tryptase inhibitors described as immune-based inflammatory disorders treatment

FK-224 research update

Leukocyte elastase inhibitors reported by Sanofi Winthrop

Pierre Fabre reports antioxidants

Glaxo Wellcome claims GR-79236 for reducing myocardial injury

BES and BENSPM claimed as vascular proliferative disorders treatment

SR-140333 claimed as a cardioregulatory drug

Alpha2-adrenoceptor agonists effective as cardiac arrest treatment

BASF reports thrombin inhibitors

D-HG: DIC/thrombosis treatment

Pharmacia & Upjohn introduces new dosage strength for Fragmin

Antithrombotic/antiallergic TxA2 synthase inhibitors from Terumo

Novo Nordisk claims xanomeline as potential urinary bladder disorder treatment

Leiras claims oral delivery system for oxybutynin chloride

Anti-H. pylori cephem compounds described by Fujisawa

Thiophene and thiophene derivatives described by Sankyo as ulcer treatment

Anti-H. pylori compound from Toyama

CL-316243: Claimed as gastrointestinal disorders treatment by Glaxo Wellcome

Selective beta3-adrenoceptor agonists in Dainippon's pipeline

Phase III results indicate Ergoset's effectiveness and safety

ALT-766: New AGE cross-link breaker from Alteon

Prostaglandin E1 regimen shows positive results for male erectile dysfunction

Comparative study results of Systen and Menorest

Raloxifene claimed as treatment for excess bradykinin-related conditions

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...